Sandra Milligan, M.D.

Sandra Milligan, M.D.

Former EVP and Head of Research and DevelopmentatOrganon & Co.· In proxies 2021–2023

Pay in FY2023+2% from the year before

Sandra Milligan, M.D. was paid $4.4M in FY2023 (Dec), up 2%.

PayNo stock prices for these years
Pay is from the Summary Compensation Table of each Organon & Co. proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Organon & Co.Public company · 5 yr
    • Former EVP and Head of Research and Development2021 – Present · 5 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?